IP Library Granted Patent US 9,675,583
Granted Patent B2
US 9,675,583 · App. 14/827,228 · Granted Jun 13, 2017

Selective androgen receptor modulators (SARMS) and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,675,583
App. No.
14/827,228
Granted
Jun 13, 2017
Kind
B2
Abstract

Provided herein are compounds, such as compounds, of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.

Claims (41)

1. A method of treating a subject having a disease, disorder or condition caused by hyperactivity of an androgen receptor, comprising:

administering to the subject a therapeutically effective amount of a compound of formula I;

wherein:

R 1 is CF 3 , F or Cl;

R 2 H or methyl; and

R 3 is H or methyl; or a pharmaceutically acceptable salt or ester thereof;

thereby treating the disease, disorder or condition; and

wherein the disease, disorder, or condition is selected from among acne, androgenetic alopecia, prostate cancer, hirsutism, hyperandrogenism, male infertility, ovarian hyperandrogenism, and seborrhea.

2. The method of claim 1 , wherein R 1 is CF 3 , R 2 is H and R 3 is H.

3. The method of claim 1 , wherein R 1 is CF 3 , R 2 is H and R 3 is methyl.

4. The method of claim 1 , wherein R 1 is CF 3 , R 2 is methyl and R 3 is hydrogen.

5. The method of claim 1 , wherein R 1 is F, R 2 is H and R 3 is H.

6. The method of claim 1 , wherein R 1 is F, R 2 is H and R 3 is methyl.

7. The method of claim 1 , wherein R 1 is F, R 2 is methyl and R 3 is hydrogen.

8. The method of claim 1 , wherein R 1 is Cl, R 2 is H and R 3 is H.

9. The method of claim 1 , wherein R 1 is Cl, R 2 is H and R 3 is methyl.

10. The method of claim 1 , wherein R 1 is Cl, R 2 is methyl and R 3 is hydrogen.

11. The method of claim 1 , wherein the compound of formula I is selected from among:

R,R-4-(2-(1-Hydroxyl-2,2,2-trifluoroethyl)pyrrolidinyl)-2-trifluoromethyl-benzonitrile;

4-(2(R)-(1(S)-hydroxyl-2,2,2-trifluoroethyl)pyrrolidinyl)-2-trifluoromethyl-benzonitrile;

R,R,R-4-(2-(1-Hydroxyl-2,2,2-trifluoroethyl)-5-methylpyrrolidinyl)-2-trifluoromethyl -benzonitrile;

4-(2(R)-(1(S)2,2,2-trifluoromethyl)-5(R)-methylpyrrolidinyl)-2-trifluoromethyl -benzonitrile;

R,R-4-(2-(1-Hydroxyl-2,2,2-trifluoroethyl)pyrrolidinyl)-2-chlorobenzonitrile;

4-(2(R)-(1(S)-hydroxyl-2,2,2-trifluoroethyl)pyrrolidinyl)-2-chlorobenzonitrile;

R,R,R-4-(2-(1-hydroxyl-2,2,2-trifluoroethyl)-5-methylpyrrolidinyl)-2-chlorobenzonitrile;

4-(2(R)-(1(S)-hydroxyl-2,2,2-trifluoroethyl)-5(R)-methylpyrrolidinyl)-2chlorobenzonitrile;

R,R-4-(2-(1-hydroxyl-2,2,2-trifluoroethyl)pyrrolidinyl)-2-chloro-3-methylbenzonitrile;

4-(2(R)-(1(S)-hydroxyl-2,2,2-trifluoroethyl)-pyrrolidinyl)-2-chloro-3-methylbenzonitrile;

3-methyl-4-((R)-2-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-(trifluoromethyl)-benzonitrile;

3-methyl4((R)-2-((S)-2,2,2-trifluoro-1-hydroxethyl)pyrrolidin-1-yl)-2(trilfuoromethyl)-benzonitrile;

3-methyl-4-((2R,5R)-2-methyl-5-((S)-2,2,2-trifluoro-1-hydroxyethyl)-pyrrolidin-1yl)-2-(trifluoromethyl)benzonitrile;

2-fluoro-4-((2R,5R)-2-methyl-5((S)-2,2,2-trifluoro-1-hydroxethyl)-pyrrolidin-1yl)-benzonitrile;

2-fluoro-3-methyl-4-((2R,5R)-2-methyl-5-((S)-2,2,2-trifluoro-1-hydroxyethyl)-pyrrolidin-1-yl)benzonitrile;

2-fluoro-3-methyl-4-((R)-2-((S)-2,2,2-trifluoro-1-hydroxyethy)pyrrolidin-1-yl)-benzonitrile;

2-fluoro-4-((R)-2-((S)-2,2,2-trifluoro-1-hydroxyehyl)pyrrolidin-1-yl)benzonitrile;

2-chloro-4- ((2R,5R)-2-methyl-5-((S)-2,2,2-trifluoro-1-hydroxyethyl)-pyrrolidin-1-yl)-benzonitrile;

2-chloro,3methyl-4-((2R,5R)-2-methyl-5-((S)-2,2,2-trifluoro-1-hydroxyethyl)-pyrrolidin-1-yl)benzonitrile;

2-chloro-3-methyl-4-((R)-2-((S)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-benzonitrile; and

2-chloro-4((R)-2-((S)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-benzonitrile;

or a pharmaceutically acceptable salt thereof.

12. The method of claim 1 , wherein the compound of formula I is 4-(2(R)-(1(S)-hydroxyl-2,2,2-trifluoroethyl)pyrrolidinyl)-2-trifluoromethyl-benzonitrile, or a pharmaceutically acceptable salt thereof.

Assignments (2)
SECURITY INTEREST Recorded Oct 18, 2023
From: CYDEX PHARMACEUTICALS, INC.; LIGAND PHARMACEUTICALS INCORPORATED; METABASIS THERAPEUTICS, INC.; PFENEX INC.
To: CITIBANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065271/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2016
From: ZHI, LIN
To: LIGAND PHARMACEUTICALS INCORPORATED
Reel/Frame 040231/0552 →